RECRUITING

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

Official Title

eVTE (Electronic Venous Thromboembolism): A Cluster, Randomized, Step-wedge Type II Hybrid Study of an Alert Recommending Extended Duration Thromboprophylaxis for At-risk Discharging Medical Patients to Prevent VTE.

Quick Facts

Study Start:2024-06-01
Study Completion:2025-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06232551

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 110 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Discharging clinician must be in one of the following iCentra electronic health record (Cerner, Kansas City, MO) positions:
  2. * Physician, nurse practitioner, or physician assistant hospitalist
  3. * Physician internal medicine
  4. * Physician family medicine
  5. * Patient age ≥ 18 years.
  6. * The encounter must be inpatient.
  7. * A signed hospital discharge order must be present.
  8. * eVTE target population criteria (increased venous thromboembolism risk, low bleeding risk) must be met
  1. * Pregnant during encounter
  2. * Discharge order completed by ineligible clinician type
  3. * Exclude all cases where the patient is being actively prescribed and intended to be discharged on the following qualifying anticoagulant medications, regardless of dose form or dosing regimen (i.e., they have an active prescription for one of these medications):
  4. * Apixaban
  5. * Dabigatran
  6. * Dalteparin
  7. * Enoxaparin
  8. * Edoxaban
  9. * Betrixaban
  10. * Fondaparinux
  11. * Rivaroxaban
  12. * Warfarin
  13. * Creatinine clearance \<30 milliliters/minute based on last-available eligible serum creatinine value preceding discharge
  14. * Estimated creatine clearance based on actual body weight (preferred) ((140 - age years) \* measured weight kilograms) / (72.0 \* serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute
  15. * If measured body weight not available, then based on ideal body weight ((140 - age years) \* ideal body weight kilograms) / (72.0 \* serum creatine milligrams/deciliter) (\*0.85 if female)) = milliliters/minute

Contacts and Locations

Study Contact

Valerie Aston, MBA
CONTACT
801-507-4606
valerie.aston@imail.org
Carlos Barbagelata, MS
CONTACT
801-507-4607
carlos.barbagelata@imail.org

Principal Investigator

Scott C. Woller, MD
PRINCIPAL_INVESTIGATOR
Intermountain Health

Study Locations (Sites)

Intermountain Medical Center
Murray, Utah, 84107
United States

Collaborators and Investigators

Sponsor: Scott C. Woller, MD

  • Scott C. Woller, MD, PRINCIPAL_INVESTIGATOR, Intermountain Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-01
Study Completion Date2025-09-30

Study Record Updates

Study Start Date2024-06-01
Study Completion Date2025-09-30

Terms related to this study

Keywords Provided by Researchers

  • post-discharge
  • extended duration thromboprophylaxis
  • rivaroxaban
  • direct oral anticoagulant
  • medical patient

Additional Relevant MeSH Terms

  • Venous Thromboembolic Disease
  • Pulmonary Embolism and Thrombosis
  • Deep Vein Thrombosis
  • Hospitalism